Amgen: FDA Broadens Approved Use Of Repatha

(RTTNews) - Amgen (AMGN) announced the FDA has broadened the approved use of Repatha or evolocumab to include adults at increased risk for major adverse cardiovascular events due to uncontrolled low-density lipoprotein cholesterol. The update removes a prior requirement for a patient to have been diagnosed with cardiovascular disease.

Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, said: "This label update highlights the real-world need for additional treatment options for at-risk patients. Repatha is an effective therapy for reducing LDL-C, particularly in patients whose disease remains uncontrolled with statins or who cannot tolerate them."

For More Such Health News, visit rttnews.com.